We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

German perspective on new EU clinical trials regulation

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • October 29 2014

On June 16 2014 EU Regulation 5362014 on Clinical Trials on Medicinal Products for Human Use entered into force. Once it becomes applicable, the

Pricing for new innovative drugs public payers attempt new approach

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • June 18 2014

In 2011 an additional benefit assessment for innovative drugs and consecutive price negotiations known as the AMNOG procedure entered into force

Generic drug and API producers deal with the Bolar exemption

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • February 26 2014

To allow generic drug companies to enter the market as seamlessly as possible after expiration of patent rights, the Bolar exemption allows certain

Yet another health reform and seizure of retiring doctors' practices

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • February 19 2014

The new German government intends to increase competition in the healthcare sector by varying insurance premiums

An end to free pricing in the German pharmaceuticals market

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • November 22 2010

Germany has long been the only country in Europe that allows pharmaceutical producers to determine freely their prices for new, supposedly innovative products

The convergence of transatlantic health care systems and resulting real estate opportunities

  • McDermott Will & Emery
  • -
  • Germany, USA
  • -
  • July 6 2009

Health care systems on both sides of the Atlantic are converging

Ownership and operation of pharmacies can be restricted to pharmacists alone

  • McDermott Will & Emery
  • -
  • Austria, European Union, Germany
  • -
  • May 22 2009

In two recent cases, Commission v Italy and Apothekerkammer des Saarlandes and Others, the European Court of Justice (ECJ) found that the Italian and German legislation providing that only pharmacists may own and operate a pharmacy, is justified by the objective of ensuring that the provision of medicinal products to the public is reliable and of good quality

The relationship between doctors and the commercial health care industry in Germany

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • April 29 2008

The scientific and medical communities overlap, and cooperative medical research is constantly growing in size and importance

German Federal Patent Court invalidates Pfizer’s Lipitor patent

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • December 28 2007

Invalidating all relevant claims of the patent-in-suit, the Federal Patent Court of Germany handed down a decision for Ranbaxy Laboratories’ German subsidiary Basics GmbH in its case against Warner Lambert’s European Patent 0,409,281 (EP ’281) owned by Pfizer

The liberalization of the German health care service sector

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • June 7 2007

The introduction of the medical ambulatory service center has changed Germany’s health care industry in ways not seen since 2003